Showing 5561-5570 of 21485 results for "".
- Capricor Announces Late‑Breaking HOPE‑3 Phase 3 Presentation at MDA 2026https://reachmd.com/news/capricor-announces-latebreaking-hope3-phase-3-presentation-at-mda-2026/2485834/Capricor Therapeutics reported that results from its Phase 3 HOPE‑3 cl
- Erectile Dysfunction as an Early Marker of Cardiovascular Riskhttps://reachmd.com/news/erectile-dysfunction-as-an-early-marker-of-cardiovascular-risk/2485872/Erectile dysfunction (ED) is now being framed as a vascular symptom that may appear before overt cardiovascular disease (CVD) and, in that context, signal higher risk for later events. The authors describe ED and CVD as clinically intertwined through shared risk factors a
- Sex Differences in Coronary Plaque Burden and Event Risk (PROMISE Subset)https://reachmd.com/news/sex-differences-in-coronary-plaque-burden-and-event-risk-promise-subset/2485821/In a PROMISE trial subset, investigators reported that women undergoing coronary CT angiography had less overall coronary plaque than men, yet their subsequent clinical eve
- Preclinical Nasal Spray Boosts Mucosal Defense and Blocks Allergic Responses in Micehttps://reachmd.com/news/preclinical-nasal-spray-boosts-mucosal-defense-and-blocks-allergic-responses-in-mice/2485812/An intranasal formulation described as GLA-3M-052-LS+OVA was reported in a Stanford Medicine mouse study to “supercharge” airway and mucosal defenses, with the write-up describing bro
- WiQo US Expands Midwest Footprint Through Exclusive Partnership With Synergy Aestheticshttps://reachmd.com/news/wiqo-us-expands-midwest-footprint-through-exclusive-partnership-with-synergy-aesthetics/2485815/WiQo US announced a strategic partnership with Synergy Aesthetics, granting the organization exclusive rights to represent the WiQo PRX product system across a 10-state Midwest region. The agreement covers Arkansas, Iowa, Kansas, Minnesota, Missouri, Nebraska, Nort
- New AAFPRS Data Reveals Trends Defining Facial Plastic Surgeryhttps://reachmd.com/news/new-aafprs-data-reveals-trends-defining-facial-plastic-surgery/2485807/The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) is reporting a notable shift in the aesthetic landscape, with its 2025 Annual Survey pointing to rising procedural volume alongside evolving patient priorities. According to newly released data, facial plastic surgeons nat
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://reachmd.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Triple‑Phytochemical Nanoparticle for CRC: Formulation, In Vitro Release, Safety, and Gene‑Expression Signalshttps://reachmd.com/news/triplephytochemical-nanoparticle-for-crc-formulation-in-vitro-release-safety-and-geneexpression-signals/2485787/Investigators report developing a triple-payload nanoparticle carrying resveratrol, acetyl-11-keto-β-boswellic acid (AKBA), and quercetin—referred to as the 3X nanoparticle formulation—for colore
- Understanding Sex Differences in Pain Resolutionhttps://reachmd.com/news/sex-differences-pain-resolution/2485796/Michigan State University researchers report that IL‑10–producing monocytes were observed to interact with pain-sensing neurons in a way that switches off pai
- MoonLake S-OLARIS Phase 2 Topline: Sonelokimab ASAS40 81% at Week 12https://reachmd.com/news/moonlake-s-olaris-phase-2-topline-sonelokimab-asas40-81-at-week-12/2485786/MoonLake Immunotherapeutics reports topline Phase 2 results for sonelokimab (SLK) from the